Abstract
18F-Fluorodeoxyglucose (FDG) is an analogue of glucose and is the most common PET radiotracer for oncological applications. Its wide use in clinical practice is primarily due to the Warburg effect, which leads to higher glucose consumption in the malignant cells in comparison to normal tissue. The malignancy-induced hypermetabolism is generally based upon overexpression of cellular membrane glucose transporters (mainly glucose transporter 1, GLUT-1) and enhanced hexokinase enzymatic activity in tumors [1, 2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Macheda ML, Rogers S, Bets JD (2005) Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol 202:654–662
Smith TA (2000) Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57:170–178
Effert P, Beniers AJ, Tamimi Y et al (2004) Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res 24:3057–3063
Clavo AC, Brown RS, Wahl RL (1995) Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625–1632
Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW et al (2011) Androgen stimulates glycolysis for de novo lipid synthesis by increasing activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 in prostate cancer cells. Biochem J 433:225–233
Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C et al (2011) Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 52:1654–1663
Jadvar H (2013) Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40:S5–S10
Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20(13):3001–3015
Balk SP, Ko YJ, Burbley GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21(2):383–391
Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5(5):343–354
Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxyglucose-2-[F-18]fluoro-D-glucose. Radiology 199:751–756
Yeh SD, Imbriaco M, Larson SM et al (1996) Detection of bony metastases of androgen-independent prostate cancer by PET FDG. Nucl Med Biol 23:693–697
Tiwari BP, Jangra S, Nair N et al (2010) Complimentary role of FDG PET imaging and skeletal scintigraphy in the evaluation of patients with prostate carcinoma. Indian J Cancer 47:385–390
Damle NA, Bal C, Bandopadhyaya GP et al (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung, and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31:262–269
Langsteger W, Heinisch M, Fogelman I (2006) The role of fluorodeoxyglucose, 18F-dishydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36:73–92
Bailly M, Besse H, Kerdraon R et al (2014) 18F-FDG PET/CT superscan in prostate cancer. Clin Nucl Med 39:912–914
Iagaru A, Mittra E, Yaghoubi SS et al (2009) Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 50:501–505
Lin FI, Rao JE, Mittra ES et al (2012) Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 39:262–270
Minamimoto R, Loening A, Jamali M et al (2015) Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med 56:1862–1868
Schoder H, Hermann K, Gonen M et al (2005) 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11:4761–4769
Jadvar H, Desai B, Ji L et al (2012) Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 37:637–643
Vassiliou V, Andreopoulos D, Frangos S et al (2011) Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol (R Coll Radiol) 23:632–645
Zhang Y, Saylor M, Wen S et al (2006) Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol Imaging Biol 8:300–308
Zukotynski KA, Kim CK, Gerbaudo VH et al (2014) (18F)F-FDG-PET/CT and (18F)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging 5:72–82
Simoncic U, Perlman S, Liu G et al (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castrate-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7–e17
Courtney KD, Manola JB, Elfiky AA et al (2015) A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 13:113–123
Yu EY, Muzi M, Hackenbracht JA et al (2011) C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 36:192–198
Morris MJ, Akhurst T, Osman I et al (2002) Fluoridated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59:913–918
Morris MJ, Akhurst T, Larson SM et al (2005) Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11:3210–3216
Meirelles GS, Schoder H, Ravizzini GC et al (2010) Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 16:6093–6096
Vargas HA, Wassberg C, Fox JJ et al (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271:220–229
Jadvar H, Desai B, Ji L et al (2013) Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 54:1195–1201
Jadvar H, Groshen SG, Quinn DI (2015) Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology 274:624–625
Jadvar H (2011) Prostate cancer: PET with 18F-FDG, 18F-or 11C-Acetate, and 18F- or 11C-choline. J Nucl Med 52(1):81–89
Acknowledgment
Supported in part by the United States of America National Institutes of Health grants R01-CA111613, R21-CA142426, R21-EB017568, and P30-CA014089
Financial Disclosure
No conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jadvar, H., Evangelista, L. (2017). Imaging of Glycolysis with 18F-FDG PET. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-42327-2_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42326-5
Online ISBN: 978-3-319-42327-2
eBook Packages: MedicineMedicine (R0)